A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

Detalles Bibliográficos
Autores principales: Chen, Yunxin, Gopalakrishnan, Sathish Kumar, Ooi, Melissa, Sultana, Rehena, Lim, Li Hui, Grigoropoulos, Nicholas, Ong, Shin Yeu, Xu, Mingge, Chng, Wee Joo, Goh, Yeow Tee, Nagarajan, Chandramouli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417287/
https://www.ncbi.nlm.nih.gov/pubmed/34480015
http://dx.doi.org/10.1038/s41408-021-00544-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417287/
https://www.ncbi.nlm.nih.gov/pubmed/34480015
http://dx.doi.org/10.1038/s41408-021-00544-x

Ejemplares similares